209 related articles for article (PubMed ID: 34816677)
1. The pronounced decline of anti-SARS-CoV-2 spike trimeric IgG and RBD IgG in baseline seronegative individuals six months after BNT162b2 vaccination is consistent with the need for vaccine boosters.
Salvagno GL; Henry BM; Pighi L; De Nitto S; Gianfilippi G; Lippi G
Clin Chem Lab Med; 2022 Jan; 60(2):e29-e31. PubMed ID: 34816677
[No Abstract] [Full Text] [Related]
2. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
3. Differential Dynamics of SARS-CoV-2 Binding and Functional Antibodies upon BNT162b2 Vaccine: A 6-Month Follow-Up.
Matusali G; Sberna G; Meschi S; Gramigna G; Colavita F; Lapa D; Francalancia M; Bettini A; Capobianchi MR; Puro V; Castilletti C; Vaia F; Bordi L
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215903
[TBL] [Abstract][Full Text] [Related]
4. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
5. Effect of BNT162b2 booster dose on anti-SARS-CoV-2 spike trimeric IgG antibodies in seronegative individuals.
Salvagno GL; Henry BM; Pighi L; De Nitto S; Gianfilippi G; Lippi G
Clin Chem Lab Med; 2022 May; 60(6):930-933. PubMed ID: 35303764
[TBL] [Abstract][Full Text] [Related]
6. Spike Antibody Titers Evaluation after a 2-Dose Regimen of BNT162b2 Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2.
Kayukawa S; Nanya K; Morita M; Ina K; Ota Y; Hasegawa S
Microbiol Spectr; 2021 Dec; 9(3):e0103621. PubMed ID: 34756062
[No Abstract] [Full Text] [Related]
7. B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies.
Pulvirenti F; Fernandez Salinas A; Milito C; Terreri S; Piano Mortari E; Quintarelli C; Di Cecca S; Lagnese G; Punziano A; Guercio M; Bonanni L; Auria S; Villani F; Albano C; Locatelli F; Spadaro G; Carsetti R; Quinti I
Cells; 2021 Oct; 10(11):. PubMed ID: 34831138
[TBL] [Abstract][Full Text] [Related]
8. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 Vaccine Induced Atypical Immune Responses in Antibody Defects: Everybody Does their Best.
Salinas AF; Mortari EP; Terreri S; Quintarelli C; Pulvirenti F; Di Cecca S; Guercio M; Milito C; Bonanni L; Auria S; Romaggioli L; Cusano G; Albano C; Zaffina S; Perno CF; Spadaro G; Locatelli F; Carsetti R; Quinti I
J Clin Immunol; 2021 Nov; 41(8):1709-1722. PubMed ID: 34669144
[TBL] [Abstract][Full Text] [Related]
10. Evidence of SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2 mRNA Vaccine.
Ciabattini A; Pastore G; Fiorino F; Polvere J; Lucchesi S; Pettini E; Auddino S; Rancan I; Durante M; Miscia M; Rossetti B; Fabbiani M; Montagnani F; Medaglini D
Front Immunol; 2021; 12():740708. PubMed ID: 34650563
[TBL] [Abstract][Full Text] [Related]
11. Decline of antibody titres 3 months after two doses of BNT162b2 in non-immunocompromised adults.
Erice A; Varillas-Delgado D; Caballero C
Clin Microbiol Infect; 2022 Jan; 28(1):139.e1-139.e4. PubMed ID: 34508885
[TBL] [Abstract][Full Text] [Related]
12. Investigation of Anti-SARS-CoV-2-specific IgG Levels in Breast Milk after Vaccination or COVID-19 Infection.
Temocin F; Çaycı YT; Seren C; Kuruoglu T; Atilla A; Birinci A; Tanyel E
Am J Perinatol; 2024 May; 41(S 01):e3085-e3090. PubMed ID: 37846474
[TBL] [Abstract][Full Text] [Related]
13. Cutting Edge: Serum but Not Mucosal Antibody Responses Are Associated with Pre-Existing SARS-CoV-2 Spike Cross-Reactive CD4
Meyer-Arndt L; Schwarz T; Loyal L; Henze L; Kruse B; Dingeldey M; Gürcan K; Uyar-Aydin Z; Müller MA; Drosten C; Paul F; Sander LE; Demuth I; Lauster R; Giesecke-Thiel C; Braun J; Corman VM; Thiel A
J Immunol; 2022 Mar; 208(5):1001-1005. PubMed ID: 35121642
[TBL] [Abstract][Full Text] [Related]
14. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
15. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
Front Immunol; 2021; 12():786554. PubMed ID: 35003104
[TBL] [Abstract][Full Text] [Related]
16. Neutralizing antibody titers six months after Comirnaty vaccination: kinetics and comparison with SARS-CoV-2 immunoassays.
Padoan A; Cosma C; Bonfante F; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Pagliari M; Bortolami A; Cattelan A; Cianci V; Basso D; Plebani M
Clin Chem Lab Med; 2022 Feb; 60(3):456-463. PubMed ID: 34911170
[TBL] [Abstract][Full Text] [Related]
17. Decline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls.
Hamm SR; Møller DL; Pérez-Alós L; Hansen CB; Pries-Heje MM; Heftdal LD; Hasselbalch RB; Fogh K; Madsen JR; Almagro Armenteros JJ; Knudsen AD; Poulsen JR; Frikke-Schmidt R; Hilsted LM; Sørensen E; Ostrowski SR; Harboe ZB; Perch M; Sørensen SS; Rasmussen A; Bundgaard H; Garred P; Iversen K; Nielsen SD
Front Immunol; 2022; 13():832501. PubMed ID: 35281023
[TBL] [Abstract][Full Text] [Related]
18. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
19. Population differences in antibody response to SARS-CoV-2 infection and BNT162b2 vaccination.
Shapira G; Abu Hamad R; Weiner C; Rainy N; Sorek-Abramovich R; Benveniste-Levkovitz P; Rock R; Avnat E; Levtzion-Korach O; Bar Chaim A; Shomron N
FASEB J; 2022 Apr; 36(4):e22223. PubMed ID: 35239233
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution.
Di Noia V; Pimpinelli F; Renna D; Barberi V; Maccallini MT; Gariazzo L; Pontone M; Monti A; Campo F; Taraborelli E; Di Santo M; Petrone F; Mandoj C; Ferraresi V; Ferretti G; Carlini P; Di Bella O; Conti L; La Malfa AM; Pellini R; Bracco D; Giannarelli D; Morrone A; Cognetti F
Clin Cancer Res; 2021 Dec; 27(24):6815-6823. PubMed ID: 34583970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
